Clinical Global Impression of Improvement (CGI-I) as a valid proxy measure for remission in schizophrenia: Analyses of ziprasidone clinical study data

Schizophrenia Research

Volumn 126, Issue 1-3, 2011, Pages 174-183

  Masand, Prakash ^a   O'Gorman, Cedric ^b   Mandel, Francine S ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b PFIZER INC   (United States)

Author keywords

Prediction; Remission; Schizophrenia; Ziprasidone

Indexed keywords

ZIPRASIDONE;

ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ASSESSMENT TOOL; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL STUDY; CORRELATIONAL STUDY; DRUG EFFICACY; HUMAN; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROGNOSIS; REMISSION; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; VALIDATION PROCESS;

ANTIPSYCHOTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PIPERAZINES; PREDICTIVE VALUE OF TESTS; PROXY; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE; ROC CURVE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; THIAZOLES;

EID: 79952007422     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2010.10.024     Document Type: Article

References (63)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Association, Washington, DC. Fourth Edition.
2. Amminger G.P., Resch F., Mutschlechner R., Friedrich M.H., Ernst E. Premorbid adjustment and remission of positive symptoms in first-episode psychosis. Eur. Child Adolesc. Psychiatry 1997, 6(4):212-218.
3. Andreasen N.C., Carpenter W.T., Kane J.M., Lasser R.A., Marder S.R., Weinberger D.R. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry 2005, 162(3):441-449.
4. Auslander L.A., Jeste D.V. Sustained remission of schizophrenia among community-dwelling older outpatients. Am. J. Psychiatry 2004, 161(8):1490-1493.
5. Azorin J.M. Assessment of the notion of remission in schizophrenia. Encephale 2005, 31(Pt 2):S7-S10.
6. Boter H., Peuskens J., Libiger J., Fleischhacker W.W., Davidson M., Galderisi S., Kahn R.S. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophr. Res. 2009, 115(2-3):97-103. EUFEST study group.
7. Brenner H.D., Dencker S.J., Goldstein M.J., Hubbard J.W., Keegan D.L., Kruger G., Kulhanek F., Liberman R.P., Malm U., Midha K.K. Defining treatment refractoriness in schizophrenia. Schizophr. Bull. 1990, 16(4):551-561.
8. Buckley P.F., Harvey P.D., Bowie C.R., Loebel A. The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone. Schizophr. Res. 2007, 94(1-3):99-106.
9. Carr V.J. Recovery from schizophrenia: a review of patterns of psychosis. Schizophr. Bull. 1983, 9(1):95-121.
10. Caton C.L., Hasin D.S., Shrout P.E., Drake R.E., Dominguez B., Samet S., Schanzer B. Predictors of psychosis remission in psychotic disorders that co-occur with substance use. Schizophr. Bull. 2006, 32(4):618-625.
11. Davidson L., Schmutte T., Dinzeo T., Andres-Hyman R. Remission and recovery in schizophrenia: practitioner and patient perspectives. Schizophr. Bull. 2008, 34(1):5-8.
12. De Hert M., van Winkel R., Wampers M., Kane J., van Os J., Peuskens J. Remission criteria for schizophrenia: evaluation in a large naturalistic cohort. Schizophr. Res. 2007, 92(1-3):68-73.
13. Doyle A.C., Pollack M.H. Establishment of remission criteria for anxiety disorders. J. Clin. Psychiatry 2003, 64(Suppl 15):40-45.
14. Dunayevich E., Sethuraman G., Enerson M., Taylor C.C., Lin D. Characteristics of two alternative schizophrenia remission definitions: relationship to clinical and quality of life outcomes. Schizophr. Res. 2006, 86(1-3):300-308.
15. Eaton W.W., Thara R., Federman E., Tien A. Remission and relapse in schizophrenia: the Madras Longitudinal Study. J. Nerv. Ment. Dis. 1998, 186(6):357-363.
16. Emsley R., Chiliza B., Schoeman R. Predictors of long-term outcome in schizophrenia. Curr. Opin. Psychiatry 2008, 21(2):173-177.
17. Emsley R., Oosthuizen P.P., Kidd M., Koen L., Niehaus D.J., Turner H.J. Remission in first-episode psychosis: predictor variables and symptom improvement patterns. J. Clin. Psychiatry 2006, 67(11):1707-1712.
18. Emsley R., Rabinowitz J., Medori R. Remission in early psychosis: rates, predictors, and clinical and functional outcome correlates. Schizophr. Res. 2007, 89(1-3):129-139.
19. Faerden A., Nesvag R., Marder S.R. Definitions of the term 'recovered' in schizophrenia and other disorders. Psychopathology 2008, 41(5):271-278.
20. Frank E., Prien R.F., Jarrett R.B., Keller M.B., Kupfer D.J., Lavori P.W., Rush A.J., Weissman M.M. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch. Gen. Psychiatry 1991, 48(9):851-855.
21. Gasquet I., Haro J.M., Tcherny-Lessenot S., Chartier F., Lépine J.P. Remission in the outpatient care of schizophrenia: 3-year results from the Schizophrenia Outpatients Health Outcomes (SOHO) study in France. Eur. Psychiatry 2008, 23(7):491-496.
22. Gharabawi G., Rodriquez S., Turkoz I., Simpson G. Exploring the evidence for a relationship between symptomatic remission and functioning in patients with schizophrenia. Neuropsychopharmacology 2010, 30:S126-S127.
23. Haro J.M., Ciudad A., Alonso J., Bousono M., Suarez D., Novick D., Gilaberte I. Remission and relapse in the outpatient treatment of patients with schizophrenia. Outcomes at 3years. Actas Esp. Psiquiatr. 2008, 36(4):187-196.
24. Helldin L., Kane J.M., Karilampi U., Norlander T., Archer T. Remission and cognitive ability in a cohort of patients with schizophrenia. J. Psychiatr. Res. 2006, 40(8):738-745.
25. Helldin L., Kane J.M., Karilampi U., Norlander T., Archer T. Remission in prognosis of functional outcome: a new dimension in the treatment of patients with psychotic disorders. Schizophr. Res. 2007, 93(1-3):160-168.
26. Ho B.C., Andreasen N.C., Flaum M., Nopoulos P., Miller D. Untreated initial psychosis: its relation to quality of life and symptom remission in first-episode schizophrenia. Am. J. Psychiatry 2000, 157(5):808-815.
27. Holthausen E.A., Wiersma D., Cahn W., Kahn R.S., Dingemans P.M., Schene A.H., van den Bosch R.J. Predictive value of cognition for different domains of outcome in recent-onset schizophrenia. Psychiatry Res. 2007, 149(1-3):71-80.
28. Jager M., Riedel M., Schmauss M., Laux G., Pfeiffer H., Naber D., Schmidt L.G., Gaebel W., Klosterkotter J., Heuser I., Kuhn K.U., Lemke M.R., Ruther E., Buchkremer G., Gastpar M., Bottlender R., Strauss A., Moller H.J. Prediction of symptom remission in schizophrenia during inpatient treatment. World J. Biol. Psychiatry 2009, 10(4 Pt 2):426-434.
29. Kane J., Vanderburg D., Loebel A., Roberts H., Batzar E. Early improvement with ziprasidone as a predictor of later treatment outcome in hospitalized patients with schizophrenia. Presented at: 47th Annual New Clinical Drug Evaluation Unit Meeting; June 11-14, 2007; Boca Raton, FL 2007.
30. Kane J.M., Crandall D.T., Marcus R.N., Eudicone J., Pikalov A., Carson W.H., Swyzen W. Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52weeks. Schizophr. Res. 2007, 95(1-3):143-150.
31. Kane J.M., Leucht S., Carpenter D., Docherty J.P. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J. Clin. Psychiatry 2003, 64(suppl 12):5-19.
32. Kelly D.L., Weiner E., Ball M.P., McMahon R.P., Carpenter W.T., Buchanan R.W. Remission in schizophrenia: the relationship to baseline symptoms and changes in symptom domains during a one-year study. J. Psychopharmacol. 2009, 23(4):436-441.
33. Kissling W., Heres S., Lloyd K., Sacchetti E., Bouhours P., Medori R., Llorca P.M. Direct transition to long-acting risperidone-analysis of long-term efficacy. J. Psychopharmacol. 2005, 19(5 Suppl):15-21.
34. Lambert M., Naber D., Schacht A., Wagner T., Hundemer H.P., Karow A., Huber C.G., Suarez D., Haro J.M., Novick D., Dittmann R.W., Schimmelmann B.G. Rates and predictors of remission and recovery during 3years in 392 never-treated patients with schizophrenia. Acta Psychiatr. Scand. 2008, 118(3):220-229.
35. Lambert M., Schimmelmann B.G., Naber D., Schacht A., Karow A., Wagner T., Czekalla J. Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. J. Clin. Psychiatry 2006, 67(11):1690-1697.
36. Lasser R.A., Bossie C.A., Gharabawi G.M., Kane J.M. Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection. Schizophr. Res. 2005, 77(2-3):215-227.
37. Lasser R.A., Nasrallah H., Helldin L., Peuskens J., Kane J., Docherty J., Tronco A.T. Remission in schizophrenia: applying recent consensus criteria to refine the concept. Schizophr. Res. 2007, 96(1-3):223-231.
38. Lehman A.F., Lieberman J.A., Dixon L.B., McGlashan T.H., Miller A.L., Perkins D.O., Kreyenbuhl J. Practice guideline for the treatment of patients with schizophrenia, second edition. Am. J. Psychiatry 2004, 161(2 suppl):1-56.
39. Leucht S., Beitinger R., Kissling W. On the concept of remission in schizophrenia. Psychopharmacology (Berl.) 2007, 194(4):453-461.
40. Leucht S., Lasser R. The concepts of remission and recovery in schizophrenia. Pharmacopsychiatry 2006, 39(5):161-170.
41. Liberman R., Kopelowicz A., Ventura J., Gutkind D. Operational criteria and factors related to recovery from schizophrenia. Int. Rev. Psychiatry 2002, 14:256-272.
42. Lieberman J., Jody D., Geisler S., Alvir J., Loebel A., Szymanski S., Woerner M., Borenstein M. Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch. Gen. Psychiatry 1993, 50(5):369-376.
43. Lieberman J.A., Phillips M., Gu H., Stroup S., Zhang P., Kong L., Ji Z., Koch G., Hamer R.M. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 2003, 28(5):995-1003.
44. Llorca P.M., Sacchetti E., Lloyd K., Kissling W., Medori R. Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18months. Int. J. Clin. Pharmacol. Ther. 2008, 46(1):14-22.
45. Loebel A.D., Lieberman J.A., Alvir J.M., Mayerhoff D.I., Geisler S.H., Szymanski S.R. Duration of psychosis and outcome in first-episode schizophrenia. Am. J. Psychiatry 1992, 149(9):1183-1188.
46. Malla A., Norman R., Schmitz N., Manchanda R., Bechard-Evans L., Takhar J., Haricharan R. Predictors of rate and time to remission in first-episode psychosis: a two-year outcome study. Psychol. Med. 2006, 36(5):649-658.
47. Masand P.S. A review of pharmacologic strategies for switching to atypical antipsychotics. Prim. Care Companion J. Clin. Psychiatry 2005, 7(3):121-129.
48. Masand P.S., Eudicone J., Pikalov A., McQuade R.D., Marcus R.N., Vester-Blokland E., Carlson B.X. Criteria for defining symptomatic and sustained remission in bipolar I disorder: a post-hoc analysis of a 26-week aripiprazole study (study CN138-010). Psychopharmacol. Bull. 2008, 41(2):12-23.
49. Masand P.S., Narasimhan M. Improving adherence to antipsychotic pharmacotherapy. Curr. Clin. Pharmacol. 2006, 1(1):47-56.
50. McEvoy J.P. Functional outcomes in schizophrenia. J. Clin. Psychiatry 2008, 69(Suppl 3):20-24.
51. McIntyre R.S., Fallu A., Konarski J.Z. Measurable outcomes in psychiatric disorders: remission as a marker of wellness. Clin. Ther. 2006, 28(11):1882-1891.
52. Naber D., Karow A. Good tolerability equals good results: the patient's perspective. Eur. Neuropsychopharmacol. 2001, 11(Suppl 4):S391-S396.
53. Narasimhan M., Pae C.U., Masand N., Masand P. Partial compliance with antipsychotics and its impact on patient outcomes. Int. J. Psychiatry Clin. Pract. 2007, 11(2):102-111.
54. Nasrallah H.A., Lasser R. Improving patient outcomes in schizophrenia: achieving remission. J. Psychopharmacol. 2006, 20(6 Suppl):57-61.
55. National Institute of Mental Health Schizophrenia 2007, US Department of Health and Human Services, National Institutes of Health, Bethesda, MD, (NIH publication no. 06-3517).
56. Novick D., Haro J.M., Suarez D., Lambert M., Lepine J.P., Naber D. Symptomatic remission in previously untreated patients with schizophrenia: 2-year results from the SOHO study. Psychopharmacology (Berl.) 2007, 191(4):1015-1022.
57. O'Gorman C., Kapur S., Kolluri S., Pappadolpulos E., Halmi K. Lack of early improvement demonstrates strong negative predictive value for later treatment response with atypical antipsychotics in patients with schizophrenia. Presented at: American College of Neuropsychopharmacology Meeting; December 7-11, 2008; Scottsdale, AZ 2008.
58. Perkins D., Lieberman J., Gu H., Tohen M., McEvoy J., Green A., Zipursky R., Strakowski S., Sharma T., Kahn R., Gur R., Tollefson G. Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. Br. J. Psychiatry 2004, 185:18-24.
59. Peuskens J., Kaufman L., Van Vleymen B. Analysis of resolution criteria in patients with schizophrenia treated with olanzapine for an acute psychotic episode. Schizophr. Res. 2007, 95(1-3):169-173.
60. Santarlasci B., Messori A. Clinical trial response and dropout rates with olanzapine versus risperidone. Ann. Pharmacother. 2003, 37(4):556-563.
61. Tsang H.W., Chen E.Y. Perceptions on remission and recovery in schizophrenia. Psychopathology 2007, 40(6):469.
62. van Os J., Burns T., Cavallaro R., Leucht S., Peuskens J., Helldin L., Bernardo M., Arango C., Fleischhacker W., Lachaux B., Kane J.M. Standardized remission criteria in schizophrenia. Acta Psychiatr. Scand. 2006, 113(2):91-95.
63. van Os J., Drukker M., Campo J., Meijer J., Bak M., Delespaul P. Validation of remission criteria for schizophrenia. Am. J. Psychiatry 2006, 163(11):2000-2002.